Primaquine in vivax malaria: an update and review on management issues
- PMID: 22152065
- PMCID: PMC3306765
- DOI: 10.1186/1475-2875-10-351
Primaquine in vivax malaria: an update and review on management issues
Abstract
Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of reported resistance against primaquine containing regimens; d) evidence for combining primaquine with artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer drugs.
References
-
- Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75:402–415. - PubMed
-
- Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Purnomo, Wiady I, Leksana B, Masbar S, Richie TL, Jones TR, Tijitra E, Wignall FS, Hoffman SL. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1995;52:479–484. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources